BTG plc – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 142

More Info
									              BTG plc – Product Pipeline Review – H2 2011
                                                                                          Reference Code: GMDHC01693CDB

                                                                                                 Publication Date: NOV 2011




BTG plc – Product Pipeline Review – H2 2011                                                 GMDHC01693CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
BTG plc – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 6
      List of Figures .................................................................................................................................................................................................... 8
BTG plc Snapshot .................................................................................................................................................................................................... 9
      BTG plc Overview .............................................................................................................................................................................................. 9
      Key Information .................................................................................................................................................................................................. 9
      Key Facts ........................................................................................................................................................................................................... 9
BTG plc – Research and Development Overview ....................................................................................................................................................10
      Key Therapeutic Areas ......................................................................................................................................................................................10
BTG plc – Pipeline Review ......................................................................................................................................................................................13
      Pipeline Products by Stage of Development ......................................................................................................................................................13
      BTG plc – Pipeline Products Glance .................................................................................................................................................................14
      BTG plc – Late Stage Pipeline ..........................................................................................................................................................................14
            Registration Filed Products/Combination Treatment Modalities...................................................................................................................14
            Phase III Products/Combination Treatment Modalities ................................................................................................................................15
      BTG plc Clinical Stage Pipeline Products ..........................................................................................................................................................16
            Phase II Products/Combination Treatment Modalities .................................................................................................................................16
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................17
      BTG plc–Early Stage Pipeline Products ............................................................................................................................................................18
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................18
BTG plc – Drug Profiles ...........................................................................................................................................................................................19
      Angiotensin Therapeutic Vaccine + CoVaccine HT............................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
      BGC20-0166 .....................................................................................................................................................................................................20
            Product Description ....................................................................................................................................................................................20
            Mechanism of Action...................................................................................................................................................................................20
            R&D Progress .............................................................................................................................................................................................20
      BGC20-0582 .....................................................................................................................................................................................................22
            Product Description ....................................................................................................................................................................................22
            Mechanism of Action...................................................................................................................................................................................22
            R&D Progress .............................................................................................................................................................................................22
      BGC20-1259 .....................................................................................................................................................................................................23
            Product Description ....................................................................................................................................................................................23
            Mechanism of Action...................................................................................................................................................................................23
            R&D Progress .............................................................................................................................................................................................23
      BGC20-1531 .....................................................................................................................................................................................................24
            Product Description ....................................................................................................................................................................................24
            Mechanism of Action...................................................................................................................................................................................24
            R&D Progress .............................................................................................................................................................................................24
      BTG6001 ..........................................................................................................................................................................................................25
            Product Description ....................................................................................................................................................................................25
            Mechanism of Action...................................................................................................................................................................................25
            R&D Progress .............................................................................................................................................................................................25
      CoVaccine HT ...................................................................................................................................................................................................26




BTG plc – Product Pipeline Review – H2 2011                                                                                                                 GMDHC01693CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
BTG plc – Product Pipeline Review



           Product Description ....................................................................................................................................................................................26
           Mechanism of Action...................................................................................................................................................................................26
           R&D Progress .............................................................................................................................................................................................26
     DC Bead ...........................................................................................................................................................................................................28
           Product Description ....................................................................................................................................................................................28
           Mechanism of Action...................................................................................................................................................................................28
           R&D Progress .............................................................................................................................................................................................28
     GLP-1 Peptide ..................................................................................................................................................................................................29
           Product Description ....................................................................................................................................................................................29
           Mechanism of Action...................................................................................................................................................................................29
           R&D Progress .............................................................................................................................................................................................29
     OncoGel............................................................................................................................................................................................................30
           Product Description ....................................................................................................................................................................................30
           Mechanism of Action...................................................................................................................................................................................30
           R&D Progress .............................................................................................................................................................................................30
     OncoGel + Cisplatin + 5-Fluorouracil + Radiation Therapy ................................................................................................................................31
           Product Description ....................................................................................................................................................................................31
           Mechanism of Action...................................................................................................................................................................................31
           R&D Progress .............................................................................................................................................................................................31
     Pleneva .............................................................................................................................................................................................................33
           Product Description ....................................................................................................................................................................................33
           Mechanism of Action...................................................................................................................................................................................33
           R&D Progress .............................................................................................................................................................................................33
     Prolarix..............................................................................................................................................................................................................34
           Product Description ....................................................................................................................................................................................34
           Mechanism of Action...................................................................................................................................................................................34
           R&D Progress .............................................................................................................................................................................................34
     Varisolve ...........................................................................................................................................................................................................35
           Product Description ....................................................................................................................................................................................35
           Mechanism of Action...................................................................................................................................................................................35
           R&D Progress .............................................................................................................................................................................................35
     Voraxaze...........................................................................................................................................................................................................37
           Product Description ....................................................................................................................................................................................37
           Mechanism of Action...................................................................................................................................................................................37
           R&D Progress .............................................................................................................................................................................................37
BTG plc – Pipeline Analysis.....................................................................................................................................................................................38
     BTG plc – Pipeline Products by Therapeutic Class............................................................................................................................................38
     BTG plc - Pipeline Products By Target ..............................................................................................................................................................40
     BTG plc – Pipeline Products by Route of Administration ...................................................................................................................................42
     BTG plc – Pipeline Products by Molecule Type .................................................................................................................................................43
BTG plc – Recent Pipeline Updates........................................................................................................................................................................44
BTG plc - Dormant Projects .....................................................................................................................................................................................45
BTG plc - Discontinued Pipeline Products ...............................................................................................................................................................46
     Discontinued Pipeline Product Profiles ..............................................................................................................................................................46
           Angiotensin Therapeutic Vaccine ................................................................................................................................................................46
           BGC20-1259...............................................................................................................................................................................................46
           BGC20-1531...............................................................................................................................................................................................47
           BTG-6228 ...................................................................................................................................................................................................47




BTG plc – Product Pipeline Review – H2 2011                                                                                                                GMDHC01693CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(3)
BTG plc – Product Pipeline Review



           BTG6001 ....................................................................................................................................................................................................47
           Methotrexate + Leucovorin + Voraxaze .......................................................................................................................................................47
           OncoGel .....................................................................................................................................................................................................48
           Prolarix .......................................................................................................................................................................................................48
BTG plc – Company Statement ...............................................................................................................................................................................49
BTG plc – Locations And Subsidiaries .....................................................................................................................................................................50
     Head Office .......................................................................................................................................................................................................50
     Other Locations & Subsidiaries .........................................................................................................................................................................50
BTG plc - Key Manufacturing Facilities ....................................................................................................................................................................52
Recent Developments .............................................................................................................................................................................................53
           Aug 31, 2010: BTG Signs Agreement With Nycomed For Marketing Rights Of CroFab ..............................................................................53
           Aug 31, 2010: BTG Signs Agreement With Nycomed For Marketing Rights Of DigiFab ..............................................................................53
           Jan 30, 2008: BTG plc Commences First Clinical Study Of Novel Migraine Treatment ...............................................................................54
           Jan 27, 2006: BTG Licenses Analgesic Compounds From Asterand...........................................................................................................54
           May 22, 2007: BTG Withdraws Its Marketing Authorisation Application For Voraxaze, Europe ...................................................................55
           Jan 22, 2007: BTG's Plevitrexed Shows Promising Efficacy And Tolerability In Phase I/II Study .................................................................56
           Jan 21, 2010: BTG Plc Commences Phase IIa Study Of Pleneva For Multiple Sclerosis.............................................................................57
           Nov 20, 2008: Voraxaze Rolling BLA Submission Initiated With The US FDA .............................................................................................57
           Sep 20, 2011: FDA Accepts Biologics License Application File For Voraxaze And Grants Priority Review ..................................................58
           Sep 16, 2010: BTG Initiates First Varisolve US Phase III Trial For Treatment Of Varicose Veins ................................................................58
           Dec 15, 2005: BTG Initiates Proof Of Mechanism Clinical Study For Its Novel Drug Therapy For Obstructive Sleep Apnoea......................59
           Mar 14, 2002: BTG Acquires New Class Of Compounds With Potent Antiviral Activity Against HIV From French Research .......................60
           Dec 13, 2004: KetoCytonyx Reports Positive Phase I Study Of Neuroprotectant ........................................................................................61
           Jul 11, 2003: BTG Tackles Gastric Cancer With Novel Anti-Cancer Agent BGC 9331 ................................................................................61
           Jan 11, 2007: BTG International Ltd Provides An Update On Progress With Voraxaze ...............................................................................62
           Apr 10, 2008: BTG Reports Positive Results From First Study Investigating BGC20-0166 In Obstructive Sleep Apnoea Patients ..............62
           Jul 07, 2004: KetoCytonyx Commences Phase I Study for Neuroprotectant KTX........................................................................................63
           Jun 07, 2007: Plevitrexed (BGC 9331) Receives Orphan Drug Status For Ovarian And Gastric Cancer Indications ..................................64
           Oct 04, 2006: SAFC Gets Appointed by BTG PLC To Provide Chemical Development Services ................................................................64
           Feb 04, 2010: BTG Receives First European Regulatory Approval For DigiFab ..........................................................................................65
Financial Deals Landscape......................................................................................................................................................................................66
     BTG plc, Deals Summary ..................................................................................................................................................................................66
BTG plc, Pharmaceuticals & Healthcare, Deal Details .............................................................................................................................................69
     Asset Transactions............................................................................................................................................................................................69
           Biocompatibles International Acquires Bead Technology Patents From BioCure ........................................................................................69
           Biocompatibles I
								
To top